NCT07364422

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

A Multicenter, Open-label, Single-arm, Dose-finding and Expansion Phase 1b/2 Study to Evaluate the Safety and Tolerability of JPI-547 in Combination With Irinotecan as a Third Line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 49 (estimated)
• Sponsor: Onconic Therapeutics Inc. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer

Conditions

• Gastric Cancer (GC)

Interventions

Type	Name	Description
DRUG	JPI-547	The dose levels will be escalated following a 3+3 dose escalation scheme.
DRUG	Irinotecan (drug)	The dose levels will be escalated following a 3+3 dose escalation scheme.

Timeline

• Start date: 2026-02-27
• Primary completion: 2026-02-28
• Completion: 2029-02-28
• First posted: 2026-01-23
• Last updated: 2026-01-23

Locations

1 site across 1 country: South Korea